These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 28779874

  • 1. MET Exon 14 Alterations and New Resistance Mutations to Tyrosine Kinase Inhibitors: Risk of Inadequate Detection with Current Amplicon-Based NGS Panels.
    Poirot B, Doucet L, Benhenda S, Champ J, Meignin V, Lehmann-Che J.
    J Thorac Oncol; 2017 Oct; 12(10):1582-1587. PubMed ID: 28779874
    [Abstract] [Full Text] [Related]

  • 2. Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non-small-cell Lung Cancer.
    Kim EK, Kim KA, Lee CY, Kim S, Chang S, Cho BC, Shim HS.
    Clin Lung Cancer; 2019 Jan; 20(1):e123-e132. PubMed ID: 30391211
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer.
    Guibert N, Hu Y, Feeney N, Kuang Y, Plagnol V, Jones G, Howarth K, Beeler JF, Paweletz CP, Oxnard GR.
    Ann Oncol; 2018 Apr 01; 29(4):1049-1055. PubMed ID: 29325035
    [Abstract] [Full Text] [Related]

  • 6. Prospective Clinical Integration of an Amplicon-Based Next-Generation Sequencing Method to Select Advanced Non-Small-Cell Lung Cancer Patients for Genotype-Tailored Treatments.
    Zugazagoitia J, Rueda D, Carrizo N, Enguita AB, Gómez-Sánchez D, Díaz-Serrano A, Jiménez E, Mérida A, Calero R, Lujan R, De Miguel E, Gámez P, Díaz-Hellín V, Nuñez JA, Iglesias L, Ferrer I, Paz-Ares L, Ponce-Aix S.
    Clin Lung Cancer; 2018 Jan 01; 19(1):65-73.e7. PubMed ID: 28780976
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium.
    Guo R, Berry LD, Aisner DL, Sheren J, Boyle T, Bunn PA, Johnson BE, Kwiatkowski DJ, Drilon A, Sholl LM, Kris MG.
    J Thorac Oncol; 2019 Sep 01; 14(9):1666-1671. PubMed ID: 31228623
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Detection of MET Exon 14 Skipping Alterations in Lung Cancer Clinical Samples Using a PCR-Based Approach.
    Sui JSY, Finn SP, Gray SG.
    Methods Mol Biol; 2021 Sep 01; 2279():145-155. PubMed ID: 33683691
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Alterations in the PI3K Pathway Drive Resistance to MET Inhibitors in NSCLC Harboring MET Exon 14 Skipping Mutations.
    Jamme P, Fernandes M, Copin MC, Descarpentries C, Escande F, Morabito A, Grégoire V, Jamme M, Baldacci S, Tulasne D, Kherrouche Z, Cortot AB.
    J Thorac Oncol; 2020 May 01; 15(5):741-751. PubMed ID: 32169477
    [Abstract] [Full Text] [Related]

  • 13. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.
    Frampton GM, Ali SM, Rosenzweig M, Chmielecki J, Lu X, Bauer TM, Akimov M, Bufill JA, Lee C, Jentz D, Hoover R, Ou SH, Salgia R, Brennan T, Chalmers ZR, Jaeger S, Huang A, Elvin JA, Erlich R, Fichtenholtz A, Gowen KA, Greenbowe J, Johnson A, Khaira D, McMahon C, Sanford EM, Roels S, White J, Greshock J, Schlegel R, Lipson D, Yelensky R, Morosini D, Ross JS, Collisson E, Peters M, Stephens PJ, Miller VA.
    Cancer Discov; 2015 Aug 01; 5(8):850-9. PubMed ID: 25971938
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Optimization of Routine Testing for MET Exon 14 Splice Site Mutations in NSCLC Patients.
    Descarpentries C, Leprêtre F, Escande F, Kherrouche Z, Figeac M, Sebda S, Baldacci S, Grégoire V, Jamme P, Copin MC, Tulasne D, Cortot AB.
    J Thorac Oncol; 2018 Dec 01; 13(12):1873-1883. PubMed ID: 30195702
    [Abstract] [Full Text] [Related]

  • 17. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.
    Ou SI, Young L, Schrock AB, Johnson A, Klempner SJ, Zhu VW, Miller VA, Ali SM.
    J Thorac Oncol; 2017 Jan 01; 12(1):137-140. PubMed ID: 27666659
    [Abstract] [Full Text] [Related]

  • 18. Anaplastic Lymphoma Kinase Testing: IHC vs. FISH vs. NGS.
    Niu X, Chuang JC, Berry GJ, Wakelee HA.
    Curr Treat Options Oncol; 2017 Nov 16; 18(12):71. PubMed ID: 29143897
    [Abstract] [Full Text] [Related]

  • 19. Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing.
    Jin Y, Shao Y, Shi X, Lou G, Zhang Y, Wu X, Tong X, Yu X.
    Oncotarget; 2016 Sep 20; 7(38):61755-61763. PubMed ID: 27528220
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.